A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Recruiting now · Phase 3

Conditions studied: Atopic Dermatitis

In brief

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

Key facts

Study ID
NCT06807281
Run by
Pfizer
People needed
500
Starts
2025-12-02
Expected to finish
2032-02-22
Last updated by the study team
2026-07-22

Who can join

Age: 2 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.